Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study | Infectious Diseases | JAMA Neurology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
1.
Brooks  BRWalker  DL Progressive multifocal leukoencephalopathy.  Neurol Clin 1984;2 (2) 299- 313PubMedGoogle Scholar
2.
Padgett  BLWalker  DLZuRhein  GMEckroade  RJDessel  BH Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy.  Lancet 1971;1 (7712) 1257- 1260PubMedGoogle ScholarCrossref
3.
Astrom  KEMancall  ELRichardson  EP  Jr Progressive multifocal leuko-encephalopathy: a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease.  Brain 1958;81 (1) 93- 111PubMedGoogle ScholarCrossref
4.
Aksamit  AJ Review of progressive multifocal leukoencephalopathy and natalizumab.  Neurologist 2006;12 (6) 293- 298PubMedGoogle ScholarCrossref
5.
Kleinschmidt-DeMasters  BKTyler  KL Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.  N Engl J Med 2005;353 (4) 369- 374PubMedGoogle ScholarCrossref
6.
Langer-Gould  AAtlas  SWGreen  AJBollen  AWPelletier  D Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.  N Engl J Med 2005;353 (4) 375- 381PubMedGoogle ScholarCrossref
7.
Stüve  O The effects of natalizumab on the innate and adaptive immune system in the central nervous system.  J Neurol Sci 2008;274 (1-2) 39- 41PubMedGoogle ScholarCrossref
8.
Ransohoff  RM Natalizumab and PML.  Nat Neurosci 2005;8 (10) 1275PubMedGoogle ScholarCrossref
9.
Yousry  TAMajor  EORyschkewitsch  C  et al.  Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.  N Engl J Med 2006;354 (9) 924- 933PubMedGoogle ScholarCrossref
10.
Panzara  MBaldinetti  FBelcher  G  et al.  Natalizumab utilization and safety in patients with relapsing multiple sclerosis: updated results from TOUCH™ and TYGRIS.  Mult Scler 2008;14(suppl 1)S172(P488)Google Scholar
11.
Gold  R Occurrence of progressive multifocal leukoencephalopathy in two patients relapsing-remitting MS treated with natalizumab: late breaking news.  Mult Scler 2008;14 ((suppl 1)) OP 84Google Scholar
12.
Hauser  SLWaubant  EArnold  DL  et al. HERMES Trial Group, B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.  N Engl J Med 2008;358 (7) 676- 688PubMedGoogle ScholarCrossref
13.
 Information for Healthcare Professionals Rituximab (marketed as Rituxan) Information.  US Food and Drug Administration Center for Drug Evaluation and Research Web site. http://www.fda.gov/cder/drug/InfoSheets/HCP/rituximab.htm. Published December 2006. Accessed 2008Google Scholar
14.
Molloy  ESCalabrese  LH Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?  Autoimmun Rev 2008;8 (2) 144- 146PubMedGoogle ScholarCrossref
15.
Davies  SLMoral  MA Spotlight on: clinical development of mycophenolate mofetil in multiple sclerosis.  Drug News Perspect 2006;19 (10) 632- 633PubMedGoogle ScholarCrossref
16.
Pagnoux  CHayem  GRoux  F  et al.  JC virus leukoencephalopathy complicating Wegner's granulomatosis.  Joint Bone Spine 2003;70 (5) 376- 379PubMedGoogle ScholarCrossref
17.
Warnatz  KPeter  HHSchumacher  M  et al.  Infectious CNS disease as a differential diagnosis is systemic rheumatic diseases: three case reports and a review of the literature.  Ann Rheum Dis 2003;62 (1) 50- 57PubMedGoogle ScholarCrossref
18.
Berger  JRHouff  S Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab.  Neurol Res 2006;28 (3) 299- 305PubMedGoogle ScholarCrossref
19.
Kappos  LBates  DHartung  HP  et al.  Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.  Lancet Neurol 2007;6 (5) 431- 441PubMedGoogle ScholarCrossref
20.
Filippi  MRocca  MARizzo  G  et al.  Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium.  Neurology 1998;50 (5) 1289- 1293PubMedGoogle ScholarCrossref
21.
Filippi  MIannucci  GTortorella  C  et al.  Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI.  Neurology 1999;52 (3) 588- 594PubMedGoogle ScholarCrossref
22.
McDonald  WICompston  AEdan  G  et al.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.  Ann Neurol 2001;50 (1) 121- 127PubMedGoogle ScholarCrossref
23.
Hommel  G A stagewise rejective multiple test procedure based on a modified Bonferroni test.  Biometrika 1988;75 (2) 383- 386Google ScholarCrossref
24.
Barkhof  FFilippi  MMiller  DH  et al.  Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.  Brain 1997;120 (pt 11) 2059- 2069PubMedGoogle ScholarCrossref
25.
Whiteman  MLPost  MJBerger  JRTate  LGBell  MDLimonte  LP Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation.  Radiology 1993;187 (1) 233- 240PubMedGoogle ScholarCrossref
26.
Berger  JRPall  LLanska  DWhiteman  M Progressive multifocal leukoencephalopathy in patients with HIV infection.  J Neurovirol 1998;4 (1) 59- 68PubMedGoogle ScholarCrossref
27.
Huang  DCossoy  MLi  M  et al.  Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients.  Ann Neurol 2007;62 (1) 34- 39PubMedGoogle ScholarCrossref
28.
Chowdhary  SChalmers  LMChamberlain  M Non-HIV-related progressive multifocal leukoencephalopathy (PML): a tertiary cancer center experience.  J Neuroimaging 2007;17 (1) 69- 73PubMedGoogle ScholarCrossref
29.
Hoffmann  CHorst  HAAlbrecht  HSchlote  W Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment.  J Neurol Neurosurg Psychiatry 2003;74 (8) 1142- 1144PubMedGoogle ScholarCrossref
30.
Vendrely  ABienvenu  BGasnault  JThiebault  JBSalmon  DGray  F Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy.  Acta Neuropathol 2005;109 (4) 449- 455PubMedGoogle ScholarCrossref
31.
Martinez  JVMazziotti  JVEfron  ED  et al.  Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder.  Neurology 2006;67 (9) 1692- 1694PubMedGoogle ScholarCrossref
32.
Bernal-Cano  FJoseph  JTKoralnik  IJ Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient.  J Neurovirol 2007;13 (5) 474- 476PubMedGoogle ScholarCrossref
33.
Moll  NMRietsch  AMRansohoff  AJ  et al.  Cortical demyelination in PML and MS: similarities and differences.  Neurology 2008;70 (5) 336- 343PubMedGoogle ScholarCrossref
34.
Barkhof  FScheltens  PFrequin  ST  et al.  Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity.  AJR Am J Roentgenol 1992;159 (5) 1041- 1047PubMedGoogle ScholarCrossref
35.
Morgen  KJeffries  NOStone  R  et al.  Ring-enhancement in multiple sclerosis: marker of disease severity.  Mult Scler 2001;7 (3) 167- 171PubMedGoogle ScholarCrossref
36.
Filippi  MRocca  MA Magnetization transfer magnetic resonance imaging in the assessment of neurological diseases.  J Neuroimaging 2004;14 (4) 303- 313PubMedGoogle ScholarCrossref
37.
Schmierer  KScaravilli  FAltmann  DRBarker  GJMiller  DH Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain.  Ann Neurol 2004;56 (3) 407- 415PubMedGoogle ScholarCrossref
38.
Kasner  SEGaletta  SL McGowan  JCGrossman  RI Magnetization transfer imaging in progressive multifocal leukoencephalopathy.  Neurology 1997;48 (2) 534- 536PubMedGoogle ScholarCrossref
39.
Armand  JPDousset  VFranconi  JM  et al.  Progressive multifocal leukoencephalopathy: study of the demyelination by magnetization transfer [in French].  J Radiol 1997;78 (2) 131- 134PubMedGoogle Scholar
40.
De Stefano  NNarayanan  SFrancis  GS  et al.  Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability.  Arch Neurol 2001;58 (1) 65- 70PubMedGoogle ScholarCrossref
41.
Pike  GBDe Stefano  NNarayanan  S  et al.  Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images.  Radiology 2000;215 (3) 824- 830PubMedGoogle ScholarCrossref
42.
Chen  JTCollins  DLAtkins  HLFreedman  MSArnold  DLCanadian MS/BMT Study Group, Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions.  Ann Neurol 2008;63 (2) 254- 262PubMedGoogle ScholarCrossref
43.
Khatri  B FRKoo  ALynn  FDuda  PJurgensen  SPanzara  MGiovannoni  G Plasma exchange accelerates the decline of serum natalizumab concentration in patients with multiple sclerosis: results of the Natalizumab PLEX Study.  Neurology 2008;70 (11) ((supp 1)) A227- A228Google Scholar
44.
Stüve  OMarra  CMCravens  PD  et al.  Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions.  Arch Neurol 2007;64 (2) 169- 176PubMedGoogle ScholarCrossref
Original Contribution
May 2009

Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study

Author Affiliations

Author Affiliations: Image Analysis Laboratory, Multiple Sclerosis Center, Department of Neurology (Drs Boster, Tselis, Zak, Perumal, and Khan and Mss Hreha, Bao, Penmesta, Endress, and Caon), Department of Radiology (Dr Zak), and Department of Physical Medicine and Rehabilitation and Division of Biostatistics and Clinical Translational Science (Dr Millis), Wayne State University School of Medicine, The Detroit Medical Center (Drs Boster, Tselis, Perumal, and Khan and Mss Hreha, Bao, Penmesta, and Caon), and Division of Infectious Diseases, Henry Ford Hospital (Dr Vazquez), Detroit, Michigan; Multiple Sclerosis Center, Division of Neuroimmunology, Department of Neurology, Ohio State University, Columbus (Drs Boster and Racke); Department of Neurology, University of Kentucky College of Medicine, Lexington (Dr Berger); and Departments of Neurology, Medicine, and Microbiology, University of Colorado Health Sciences Center and Denver Veterans Affairs Medical Center, Denver (Dr Tyler).

Arch Neurol. 2009;66(5):593-599. doi:10.1001/archneurol.2009.31
Abstract

Objective  To identify clinical and magnetic resonance imaging (MRI) features that distinguish progressive multifocal leukoencephalopathy (PML) from relapsing-remitting multiple sclerosis (RRMS).

Design  Retrospective medical record review.

Setting  Two urban teaching hospitals in Detroit, Michigan.

Patients  Forty-five confirmed PML cases and 100 patients with RRMS.

Main Outcome Measures  Clinical and MRI features distinguishing PML from RRMS.

Results  Overall, monosymptomatic presentations were more common in multiple sclerosis (MS) than PML (85% vs 47%; P < .01). However, patients with PML presented more often with hemiparesis (24% vs 5%; P = .001) and altered mentation (19% vs 0%; P < .0001), whereas brainstem (2% vs 18%; P = .007) presentations were more common in patients with RRMS. Spinal cord and optic neuritis presentations were seen in 18% and 33% of patients with RRMS, respectively, but not in patients with PML (m < .0001). Brain MRI scans, available in 35 (78%) PML cases, revealed 7 lesion types. Large, confluent T2-weighted lesions (74% vs 2%; P < .0001) and deep gray matter lesions (31% vs 7%; P < .001) were more frequent in patients with PML than patients with RRMS. Crescentic cerebellar lesions (23% vs 0%; P < .001) were seen only in patients with PML. Gadolinium-enhancing (23%), transcallosal (9%), and periventricular (9%) lesions were noted in patients with PML. Brain magnetization transfer ratio (MTR) was low in both PML and MS lesions. However, normal-appearing brain tissue MTR in PML was higher than normal-appearing brain tissue MTR in RRMS (44.15% vs 41.04%; P = .002), suggesting that PML may be relatively more focal than MS.

Conclusions  There appear to be differences between the clinical and MRI characteristics of PML and RRMS, which may help distinguish new MS activity from PML. Magnetization transfer ratio studies may provide additional clues in improving early detection of PML in patients with preexisting MS and warrant further investigation.

×